A phase 1b/2 open-label clinical trial of patients with choroidal melanoma treated with AU-011 showed a statistically significant reduction in tumor growth rate and favorable preliminary vision, according to a speaker.
“AU-011 has the potential to be the first targeted therapy for the treatment of small choroidal melanoma and indeterminate lesions,” Carol L. Shields, MD, said at Retina Subspecialty Day at the virtual American Academy of Ophthalmology meeting.
Shields presented the interim results of 56 patients treated with intravitreal administration of AU-011 (Aura Biosciences), a
Uncategorized